TUCSON, ARIZONA – February 13, 2024 – Avery Therapeutics, Inc. (“Avery”), a privately held, pre-clinical stage therapeutics company, proudly announces the successful qualification of their in-house cGMP pilot manufacturing facility for Phase I production in Tucson, AZ.
Avery Therapeutics team members collaborate in the company’s new facility.
Avery’s Chief Operating and Financial Officer, Jen Koevary, expressed her pride in the team’s dedication to quality and the effort that they put into qualifying the facility. She stated, “This is a significant milestone on our path to securing our first IND. Manufacturing products in-house not only aligns with our mission of improving lives but also keeps our team closely connected to that mission.”
The 1,000 square-foot manufacturing space is located adjacent to Avery’s R&D facilities and is equipped for biologics manufacturing, including cell culture and tissue engineering. Avery’s manufacturing team is set to produce products for use in IND enabling studies this year and will also manufacture for the future Phase I clinical trial in this facility.
About Avery Therapeutics, Inc.
Avery Therapeutics is developing therapeutics to redirect the immune system to address diseases of aging, inflammation, and fibrosis. For more information, please visit AveryThera.com and follow Avery Therapeutics on LinkedIn.
###
Media Contact:
Dan Ross